Covid-19: Dr Reddy’s collaborates with BIRAC for clinical trials of Sputnik V | News – Times of India Videos

Pharma major Dr Reddy’s Laboratories has entered into a partnership with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), government of India, for advisory support on clinical trials of Russian Covid-19 vaccine Sputnik V in India. The company said the partnership will enable it to identify and use some of BIRAC’s clinical trial centres for the vaccine, which are funded under the National Biopharma Mission (NBM), implemented by Project Management Unit-NBM at BIRAC. The company will also have access to Good Clinical Laboratory Practice (GCLP) labs to conduct immunogenicity assay testing of the vaccine thanks to the tie up. It was only in mid October 2020 that Dr Reddy’s and Russia Direct Investment Fund (RDIF) received approval from the Drugs Controller General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India. The Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia on August 11, 2020, becoming the world’s first registered vaccine against Covid-19 based on the human adenoviral vector platform.